Recordati announced agreement to acquire global rights to Enjaymo (sutimlimab) from Sanofi (top-25 pharma seller) for $825M upfront plus up to $250M in commercial milestones. Enjaymo is the only FDA-approved treatment for cold agglutinin disease (CAD), generating ~€100M TTM revenue with peak sales potential of €250-300M. Strengthens Recordati rare disease franchise.